

**Disclosure Statement:  
Joint working project between Hull and East Yorkshire Hospitals NHS Trust and Bristol-Myers Squibb Pharmaceuticals Ltd**

|                           |   |
|---------------------------|---|
| <b>Name of Project</b>    | Adverse Event Pathway Project (AEPP): Early recognition and rapid treatment of immune-related adverse events (IrAE) Joint Working Project   |
| <b>Project Overview</b>   | <p>Immuno-oncology (I-O) agents have led to a significant change and development in the way some cancers are treated. However, their side-effect profile is very different from standard chemotherapy. Side effects are generally immune related and these present in many different ways. The unfamiliarity of immune-related adverse events within the health service can lead to poor management and this will be directly linked to the outcomes of a patient.</p> <p>It is against this background that we seek to plan a service that maximises the chances of immune-related Adverse Events (IrAE) associated with I-O agents being recognised and treated quickly</p>   |
| <b>Project Objectives</b> | <p>The project intends to define how to develop a system that captures, identifies and treats the presentation of an IrAE quickly and effectively.</p> <p>The project aims to produce a peer-generated set of recommendations which describe essential elements in a service that is effective for the Early Recognition and Rapid Treatment of immune-related Adverse Events (IrAE) and which are applicable to any configuration of hospital organisation and which will make a significant contribution towards addressing the issues described above</p>  |
| <b>Patient Benefits</b>   | <ul style="list-style-type: none"> <li>• Improve patient safety by minimising the time between IrAE recognition and appropriate treatment</li> <li>• Improve patient experience through provision of a streamlined, efficient and patient focused service which includes, for example:             <ul style="list-style-type: none"> <li>• Better trained HCPs, especially those that are likely to be the first to be consulted by I-O patients experiencing an IrAE</li> <li>• Improvements in information management between patients and care providers in managing their condition. It is anticipated that this will reduce patient waiting time and increases likelihood of recognition of event as an IrAE</li> </ul> </li> <li>• Enable patients to get the most from their medicines</li> <li>• Reduce avoidable attendances at A&amp;E and admissions to hospital</li> </ul> |
| <b>Stakeholders</b>       | <p>Hull and East Yorkshire (HEY) NHS Trust</p> <p>Bristol Myers-Squibb (BMS)</p>  |
| <b>Timelines</b>          | The Project will start from the date on which the disclosure statement goes live on the BMS Pharmaceuticals Ltd website and will finish 12 months after this date.  |

ONCUK1700998-02  
Date of Preparation: September 2017